Appointments

Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.

Adult Patients:877-442-3324

Pediatric Patients:888-733-4662

Make Appointment OnlineInternational Patients

Online second opinions

Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.

Request a second opinion

Contact & Directions

Email Dana-Farber

Main Number617-632-3000

Toll-Free Number866-408-DFCI (3324)

Maps & DirectionsContact InformationSend us a Question or Comment

How to Help

Discover the ways to give and how to get involved to support Dana-Farber.

Learn More
Give now
  • secondary banner - 4
     
  • Collaborating with the Center for Cancer Genome Discovery (CCGD)

    One of the goals of the Center for Cancer Genome Discovery (CCGD) is to provide basic, translational, and clinical investigators with access to our technologies. In this role, CCGD participates in the design, execution, and analysis of both targeted and whole genome-focused projects.

    Collaboration with CCGD offers access to cutting-edge genomic technology platforms and data analysis tools, as well as guidance in experimental design by experts in the field of cancer genomics. Not just Dana-Farber researchers, but all researchers and clinicians focusing on cancer, will have access to CCGD's technologies.

    Submission process for collaborations

    Collaborators should contact CCGD's Associate Director, Aaron Thorner, PhD, or Scientific Director, Laura MacConaill, PhD, to outline their experimental proposal. Following discussions with the appropriate CCGD members, the collaborator will submit a proposal form for review by the Proposal Evaluation Committee (PEC).

    scientific articles

    Review process for collaborations

    The PEC will conduct a review of proposed collaborations. The PEC is composed of the directors and CCGD faculty members with expertise in the particular project area, and one or more non-CCGD members within Dana-Farber. The PEC will independently review each proposal based on a number of criteria:

    • Scientific merit: highly focused on the opportunity for novel discovery and/or the opportunity for a clinically meaningful result.
    • Adequacy of sample collection and availability: Proposals should specifically outline what samples are available and the adequacy of the privacy protection of human research subjects.
    • Availability to participate in project design and execution: For example, collaborators may have lead post-doctoral fellows or staff scientists capable of participating in the execution of the project.
    • Resources available from collaborators: While the Center will support staff for many of the activities associated with the project, the CCGD will not have specific funding to execute the project.

    Policies and procedures

    The following policy statement reflects the approved operating policies and procedures established by the CCGD as summarized here and fully described in the CCGD Policies and Procedures.

    Article I: Approvals
    • It is the responsibility of the collaborating investigator to obtain approval for participation in the proposed research from the appropriate institutional officials and/or committees at all sites at which data and samples being submitted to the CCGD were collected according to applicable federal, state, and local laws and regulations, and any relevant institutional policies. This specifically includes having the proper IRB approvals and patient consent, if necessary.
    • Additionally, the collaborating investigator affirms that they will not provide the CCGD access to the identities of the donor-subjects or to information through which the identities of the donor-subjects could readily be ascertained.
    Article II: Data release
    • The CCGD recognizes that pre-publication genome sequence data is a unique and essential research resource for scientists conducting genomic research. Data release plans for the CCGD will be based on the guiding principle that pre-publication genome sequence data should be released to the scientific community as soon as data becomes available. As such, should sequence data be produced in the course of a collaborative research project, it is understood that the pre-publication genome sequence data will be made freely and publicly available via deposition to the National Center for Biotechnology Information (NCBI), a publicly-searchable, federally funded database. This policy does not pertain to experimental data generated through other core facilities; these results will remain confidential. Pre-publication of the sequence data does not preclude CCGD collaborators from the right and responsibility to publish the work in a peer-reviewed journal.
    • All collaborator results are considered confidential.
    Article III: Authorship and publications
    • The expectation in all CCGD collaborations is authorship or acknowledgement on papers and presentations resulting from the collaboration. An exact agreement regarding authorship will be determined between the CCGD and collaborator according to accepted conventions for scientific publication and formalized in the CCGD Collaboration Agreement.
    Article IV: Intellectual property
    • All intellectual property and patent issues resulting from collaboration with the CCGD will be governed by Dana-Farber Cancer Institute's regulations.